Активные метаболиты витамина D в терапии менопаузального остеопороза
Цель исследования. Провести систематический анализ литературных данных по проблеме терапии менопаузального остеопороза с помощью активных метаболитов витамина D.Кузнецова И.В.
Материал и методы. С целью проведения анализа был осуществлен поиск зарубежных и отечественных публикаций в международной системе цитирования Pubmed за последние 15 лет.
Результаты. Описаны современные теории механизма развития менопаузального остеопороза. Описаны особенности метаболизма витамина D и его эффекты на костную ткань. Приведены международные и отечественные рекомендации по терапии остеопороза. Проанализированы данные исследований, демонстрирующих возможности применения активных метаболитов витамина D в терапии менопаузального остеопороза.
Заключение. Применение активных метаболитов витамина D в виде монотерапии или в сочетании с бисфосфонатами является эффективным методом лечения женщин с менопаузальным остеопорозом с благоприятным профилем безопасности.
Ключевые слова
менопаузальный остеопороз
минеральная плотность кости
остеопоретические переломы
антирезорбтивная терапия
витамин D
активные метаболиты витамина D
альфакальцидол
Список литературы
1. Burch J.B., Augustine A.D., Frieden L.A., Hadley E., Howcroft T.K., Johnson R. et al. Advances in geroscience: impact on health span and chronic disease. J. Gerontol. A Biol. Sci. Med. Sci. 2014; 69(Suppl. 1): S1-3.
2. De Luca d’Alessandro E., Bonacci S., Giraldi G. Aging populations: the health and quality of life of the elderly. Clin. Ter. 2011; 162(1): e13-8.
3. López-Otín C., Blasco M.A., Partridge L., Serrano M., Kroemer G. The hallmarks of aging. Cell. 2013; 153: 1194-217.
4. Martin G.M. The biology of aging: 1985-2010 and beyond. FASEB J. 2011; 25(11): 3756-62.
5. Berman A.E., Leontieva O.V., Natarajan V., McCubrey J.A., Demidenko Z.N., Nikiforov M.A. Recent progress in genetics of aging, senescence and longevity: focusing on cancer-related genes. Oncotarget. 2012; 3: 1522-32.
6. Nicolson G.L. Mitochondrial dysfunction and chronic disease: treatment with natural supplements. Altern. Ther. Health Med. 2014; 20(Suppl. 1): 18-25.
7. Thorner M.O. Endocrinology of aging: the convergence of reductionist science with systems biology and integrative medicine. Front. Endocrinol. 2010; 1: 2.
8. Kanis J.A., McCloskey E.V., Johansson H., Cooper C. et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos. Int. 2013; 24: 23-57.
9. Kanis J.A.; on behalf of the WHO Scientific Group. Assessment of osteoporosis at the primary health-care level. Technical Report. WHO Collaborating Centre, University of Sheffield, UK; 2008.
10. Kitchin B., Morgan S.L. Not just calcium and vitamin D: other nutritional considerations in osteoporosis. Curr. Rheumatol. Rep. 2007; 9(1): 85-92.
11. Rizzoli R., Bianchi M.L., Garabedian M. et al. Maximizing bone mineral mass gain during growth for the prevention of fractures in the adolescents and the elderly. Bone. 2010; 46: 294-305.
12. Adami S., Giannini S., Bianchi G., Sinigaglia L., Di Munno O., Fiore C.E. et al. Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos. Int. 2009; 20: 239-44.
13. Reid I.R. Relationships between fat and bone. Osteoporos. Int. 2008; 19(5): 595-606.
14. Aguilar-Chavez E.A., Gamez-Nava J.I., Lopez-Olivo M.A. et al. Circulating leptin and bone mineral density in rheumatoid arthritis. J. Rheumatol. 2009; 36(3): 512-6.
15. Lenora J., Lekamwasam S., Karlsson M.K. Effect of multiparity and prolonged breast-feeding on maternal bone mineral density: a community-based cross-sectional study. BMC Women’s Health. 2009; 9: 19.
16. Melton L.J., Kearns A.E., Atkinson E.J., Bolander M.E., Achenbach S.J., Huddleston J.M. et al. Secular trends in hip fracture incidence and recurrence. Osteoporos. Int. 2009; 20: 687-94.
17. Miura S., Nakamori M., Yagi M., Saavedra O.L., Ikemoto S., Yamamoto S. Daily calcium intake and physical activity status in urban women living on low incomes in Davao, Philippine: a primary study for osteoporosis prevention. J. Med. Invest. 2009; 56: 130-5.
18. Blake G.M., Fogelman I. Role of dual-energy X-ray absorptiometry in the diagnosis and treatment of osteoporosis. J. Clin. Densitom. 2007; 10: 102-10.
19. Лесняк О.М., Беневоленская Л.И. Остеопороз. Диагностика, профилактика и лечение. Российская ассоциация по остеопорозу (клинические рекомендации). М.: ГЭОТАР-Медиа; 2009. 269с.
20. Civitelli R., Armamento-Villareal R., Napoli N. Bone turnover markers: understanding their value in clinical trials and clinical practice. Osteoporos. Int. 2009; 20: 843-51.
21. Kanis J.A., McCloskey E., Johansson H., Oden A., Leslie W.D. FRAX® with and without bone mineral density. Calcif. Tissue Int. 2012; 90: 1-13.
22. Black D.M., Delmas P.D., Eastell R., Reid I.R. et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med. 2007; 356: 1809-22.
23. Silverman S.L., Chines A.A., Kendler D.L., Kung A.W. et al. Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporos. Int. 2012; 23: 351-63.
24. Kanis J.A., Johansson H., Oden A., McCloskey E.V. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone. 2009; 44: 1049-54.
25. Kanis J.A., Johansson H., Oden A., McCloskey E.V. A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX. Bone. 2010; 47: 729-35.
26. de Villiers T.J., Chines A.A., Palacios S., Lips P. et al. Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporos. Int. 2011; 22: 567-76.
27. Harris S.T., Blumentals W.A., Miller P.D. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr. Med. Res. Opin. 2008; 24: 237-45.
28. Rizzoli R., Reginster J.Y., Boonen S., Breart G. Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif. Tissue Int. 2011; 89: 91-104.
29. Pazianas M., Compston J., Huang C.L. Atrial fibrillation and bisphosphonate therapy. J. Bone Miner. Res. 2010; 25: 2-10.
30. Cardwell C.R., Abnet C.C., Cantwell M.M., Murray L.J. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA. 2010; 304: 657-63.
31. Hartle J.E., Tang X., Kirchner H.L., Bucaloiu I.D. et al. Bisphosphonate therapy, death, and cardiovascular events among female patients with CKD: a retrospective cohort study. Am. J. Kidney Dis. 2012; 59: 636-44.
32. Kanis J.A., Johansson H., Oden A., McCloskey E.V. A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX®. Osteoporos. Int. 2011; 22: 2347-55.
33. Reginster J.Y., Kaufman J.M., Goemaere S. et al. Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis. Osteoporos. Int. 2012; 23: 1115-22.
34. Stevenson M., Davis S., Lloyd-Jones M., Beverley C. The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women. Health Technol. Assess. 2007;11: 1-134.
35. Lecart M.P., Reginster J.Y. Current options for the management of postmenopausal osteoporosis. Expert Opin. Pharmacother. 2011; 12(16): 2533-52.
36. Cummings S.R., San Martin J., McClung M.R. et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 2009; 361: 756-65.
37. Middleton E.T., Steel S.A., Aye M., Doherty S.M. The effect of prior bisphosphonate therapy on the subsequent BMD and bone turnover response to strontium ranelate. J. Bone Miner. Res. 2010; 25: 455-62.
38. Ершова О.Б., Белова К.Ю., Назарова А.В. Активные метаболиты витамина D: применение при остеопорозе. Остеопороз и остеопатии. 2009;1: 27-32.
39. O’Donnell S., Moher D., Thomas K., Hanley D.A., Cranney A. Systematic review of the benefits and harms of calcitriol and alfacalcidol for fractures and falls. J. Bone Miner. Metab. 2008; 26(6): 531-42.
40. Ringe J.D., Farahmand P., Schacht E. Alfacalcidol in men with osteoporosis: a prospective, observational, 2-year trial on 214 patients. Rheumatol. Int. 2013; 3: 637-43.
41. Белая Ж.Е., Рожинская Л.Я. Бисфосфонаты в терапии постменопаузального остеопороза. Доктор.Ру. 2010; 7: 29-38.
42. Ogata M., Iwasaki N., Ide R., Takizawa M. et al. The relationship between metabolic syndrome and osteoporosis: a Review. Nutrients. 2016; 8: E347.
43. Ringe J.D., Farahmand P., Schacht E., Rozehnal A. Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin d or Aalfacalcidol alone in established post-menopausal or male osteoporosis (AAC-Trial). Rheumatol. Int. 2007;27: 425-34.
44. Orimo H., Nakamura T., Fukunaga M., Ohta H. et al. A-TOP (Adequate Treatment of Osteoporosis) research group. Effects of alendronate plus alfacalcidol in osteo- porosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT) - 02. Curr. Med. Res. Opin. 2011; 27: 1273-84.
45. Nakamura Y., Suzuki T., Kamimura M., Ikegami S., Uchiyama S., Kato H. Alfacalcidol increases the therapeutic efficacy of ibandronate on bone mineral density in Japanese women with primary osteoporosis. Tohoku J. Exp. Med. 2017; 241: 319-26.
46. Orimo H. Clinical application of 1•(OH)D3 in Japan. Aktuel Rheumatol. 1994; 19(Suppl.): 27-30.
47. Richy F., Dukas L., Schacht E. Differential effects of D-hormone analogs and native vitamin D on the risk of falls: a comparative meta-analysis. Calcif. Tissue Int. 2008; 82(2): 102-7.
48. Ringe D., Dorst A., Faber H., Schlacht E. et al. Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis. Rheumatol. Int. 2004; 24(2): 63-70.
Поступила 21.04.2017
Принята в печать 28.04.2017
Об авторах / Для корреспонденции
Ирина Всеволодовна Кузнецова, д.м.н., профессор кафедры акушерства и гинекологии № 1 лечебного факультета ФГАОУ ВПО Первый московский государственный медицинский университет им. И.М. Сеченова. Адрес: 119992, Россия, Москва, Малая Трубецкая ул., д. 8с2Для цитирования: Кузнецова И.В. Активные метаболиты витамина D в терапии менопаузального остеопороза. Акушерство и гинекология. 2017; 6: 36-34.
http://dx.doi.org/10.18565/aig.2017.6.26-34
Также по теме
